No Data
No Data
Relay Therapeutics Is Maintained at Market Outperform by JMP Securities
Relay Therapeutics Is Maintained at Market Outperform by JMP
Relay Therapeutics Price Target Cut to $21.00/Share From $24.00 by JMP Securities
Relay Therapeutics Price Target Cut to $21.00/Share From $24.00 by JMP
Express News | JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $21
JMP Securities analyst Silvan Tuerkcan maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and adjusts the target price from $24 to $21.According to TipRanks data, the analyst has a success
Market Outperform Rating Maintained for Relay Therapeutics Amidst Promising Developments of RLY-2608
Roche (RHHBY.US) abandons a SHP2 conformational inhibitor.
The partnership agreement was reached on December 14, 2020.
No Data